65,437 trials
Hypoparathyroidism · Endocrine System Diseases · Parathyroid Diseases
Primary: Efficacy - Primary Endpoint During the Blinded Period — 78.7; 4.8 Percentage of participants — p=<0.0001
Chronic Cough
Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants
Drowning
Primary: Children's Self-rescue Ability — 48 Participants — p=<.01
Mantle Cell Lymphoma
Primary: Single Agent Efficacy (as Determined by Response Rate) — 1; 2 Participants
Healthy
Primary: Maximum Measured Concentration of BI 1358894 in Plasma (Cmax) — 497; 556; 484; 604 Nanomole (nmol) / Litre (L)
Hematopoietic Cell Transplantation Recipient · Refractory B-Cell Non-Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Optimal Dose of Gemcitabine Hydrochloride Determined by Dose Limiting Toxicity — 0; 6; 20; 0 Participants
Pain, Postoperative · Thoracic · Acute Pain
Primary: The Primary Endpoint of This Study Will be 24 Hours VAS Pain Score at Rest — 4.1; 4.3; 3.3 score on a scale
Chickenpox
Primary: Concentrations of Anti-varicella Zoster Virus (VZV) Glycoprotein E (gE) Antibodies — 960; 1071; 1555; 1284 mlU/ml
Return of Motor and Sensory Blockade · Anesthesia, Spinal · Decrease Discharge Time Status Post Hemorrhoidectomy
Primary: Recovery Time — 134.1; 161.9 minutes
Small Cell Lung Cancer
Primary: Overall Survival (OS) — 15.5; 13.5 Months — p=0.0040
Peripheral T-cell Lymphoma
Primary: Overall Response Rate (ORR) as Assessed by the Investigator Using the Lugano Criteria — 53.8; 53.8 percentage of participants
Ethanol Intoxication
Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants
Pulmonary Arterial Hypertension
Primary: Change From Pulmonary Vascular Resistance (PVR) From Baseline at Week 24 — 417.2 dynes*sec/cm^5
Healthy · Pre Hypertension
Primary: Change in Plasma BNP After 6-weeks of Beta-Blocker — 45; 74 Percentage Change in Plasma BNP levels
Healthy
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 3; 3; 4; 3 Participants